Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Syndax Pharmaceuticals, with 10 buy ratings and one sell rating; the average 12-month price target is $41.80 versus a share price of $13.10.
• Syndax’s third-quarter revenue rose 81.9% year over year to $83.3 million, exceeding estimates, driven by growth in Revuforj and Niktimvo commercial revenue.
• The company remains unprofitable, reporting a $0.55-per-share loss that exceeded analyst expectations, while pipeline setbacks and a CFO transition add execution risks for investors.

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $41.80.

Several brokerages have recently commented on SNDX. UBS Group reaffirmed a "buy" rating on shares of Syndax Pharmaceuticals in a research report on Thursday, October 1st. Bank of America reissued a "buy" rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. Jefferies Financial Group reissued a "buy" rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. Weiss Ratings lowered Syndax Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, October 19th. Finally, JPMorgan Chase & Co. decreased their price objective on Syndax Pharmaceuticals from $44.00 to $40.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th.

Syndax Pharmaceuticals Trading Down 4.0%

Syndax Pharmaceuticals stock opened at $13.10 on Tuesday. Syndax Pharmaceuticals has a 52 week low of $12.80 and a 52 week high of $25.59. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 6.77. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -5.22 and a beta of 0.42. The company has a 50 day moving average price of $17.05 and a 200 day moving average price of $20.21.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.06). Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The firm had revenue of $83.30 million for the quarter, compared to analyst estimates of $81.80 million. During the same period last year, the firm earned ($0.70) earnings per share. Syndax Pharmaceuticals's revenue for the quarter was up 81.9% compared to the same quarter last year. Research analysts forecast that Syndax Pharmaceuticals will post -2.01 EPS for the current year.

Key Stories Impacting Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Commercial revenue continued to grow. Third-quarter revenue reached $83.3 million, up 82% year over year and above the roughly $81.8 million consensus estimate. Revuforj revenue increased 90% to $60.7 million, with new patients rising 20% sequentially, while Niktimvo revenue rose 47% to $67.4 million. Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Management highlighted improving commercial prospects. The earnings discussion pointed to a Revuforj rebound, continued leadership in relapsed or refractory acute leukemia, and a higher Niktimvo margin outlook. Additional revumenib data from clinical trials and real-world studies is expected in the fourth quarter, providing potential future catalysts. Syndax Commercial Update
• Neutral Sentiment: Syndax appointed a new chief financial officer. Aaron A. Ondrey will become CFO on November 9, while Keith A. Goldan will remain through year-end to support the transition. The change is not currently accompanied by a strategic shift, but investors may monitor execution during the handoff. Syndax Announces CFO Transition
• Negative Sentiment: The quarterly loss exceeded expectations. Syndax reported a loss of $0.55 per share, wider than the approximately $0.49–$0.52 analyst forecasts, despite the revenue beat. The company remains unprofitable, and the earnings call also left pipeline setbacks weighing on the broader investment case. Syndax Q3 2026 Earnings Call Transcript

Insider Activity

In related news, Director Dennis Podlesak sold 8,000 shares of the firm's stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $14.21, for a total transaction of $113,680.00. Following the completion of the sale, the director directly owned 239,763 shares in the company, valued at approximately $3,407,032.23. This trade represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SNDX. WINTON GROUP Ltd lifted its holdings in shares of Syndax Pharmaceuticals by 642.7% during the 2nd quarter. WINTON GROUP Ltd now owns 76,500 shares of the company's stock valued at $1,672,000 after buying an additional 66,200 shares during the last quarter. Jupiter Topco LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at approximately $860,000. Legal & General Group Plc bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at approximately $1,431,000. Orbimed Advisors LLC acquired a new position in Syndax Pharmaceuticals in the first quarter worth approximately $22,479,000. Finally, Man Group plc acquired a new position in Syndax Pharmaceuticals in the second quarter worth approximately $4,672,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc NASDAQ: SNDX is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax's lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.